Everolimus has shown efficacy in breast cancer by inhibiting cell growth through downregulation of the PI3K/Akt/mTOR signaling pathway, highlighting its potential as a therapeutic option for primary breast AS (122). This evidence concerns the gene MTOR and breast cancer.